This article from Cui et al., 2019 underlines once again how important mature human iPSC-derived cardiomyocytes (hiPSC-CMs) are for investigating tox effects reliably for human cancer treatment.
Knowing that children are more susceptible to reveal doxorubicin-induced cardiotoxicity, this article investigates underlying mechanisms by comparing hiPSC-CMs of 30 and 60 days in culture that were treated with doxorubicin and dexrazoxane – the recognized cardioprotective drug for treating DOX‐induced cardiotoxicity.
The results show that immature cardiomyocytes (30 days in culture) are more sensitive to DOX as a result of a higher concentration of topoisomerase IIα, which leads to more DNA damage.
Find the article here
